Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Amphastar Pharmaceuticals (DE:29A)
FRANKFURT:29A
RESEARCH TOOLSreports
Holding DE:29A?
Track your performance easily
29A Stock Chart & Stats
Day’s Range€0 - €0
52-Week Range€34.10 - €58.50
Previous Close€45.13
Volume0.00
Average Volume (3M)175.00
Market Cap
€2.16B
Enterprise Value€2.51B
Total Cash (Recent Filing)$250.49M
Total Debt (Recent Filing)$629.85M
Price to Earnings (P/E)―
Beta0.11
Next Earnings
Mar 12, 2025EPS Estimate
€0.91Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding48,081,433
10 Day Avg. Volume32
30 Day Avg. Volume175
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)2.87
Price to Sales (P/S)3.17
Price to Cash Flow (P/CF)9.60
P/FCF Ratio12.40
Enterprise Value/Market CapN/A
Enterprise Value/Revenue3.48
Enterprise Value/Gross Profit7.16
Enterprise Value/Ebitda9.44
Forecast
1Y Price Target
€63.99Price Target Upside47.21% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering3
Amphastar Pharmaceuticals News
PremiumCompany Announcements
Amphastar Pharmaceuticals Reports Strong Q3 2024 Results
PremiumCompany Announcements
Amphastar Pharmaceuticals Advances Governance and Shareholder Value
Bulls Say, Bears Say
Bulls Say
Financial Health And Growth OpportunitiesAmphastar has over $200 million of cash on the balance sheet and a net leverage ratio below 2x, indicating strong financial health and positioning the company for more tuck-in business development.
Product Market LeadershipBAQSIMI is currently the market-share-leading product in the branded glucagon market and the only non-injectable product, with additional differentiation through small product size and wider temperature storage range.
Sales Growth And ExpansionThe company plans to expand its sales force marketing BAQSIMI to more territories in the US, expecting sales growth to continue.
Bears Say
Financial Performance3Q24 results came short of Street estimates on both top-line and bottom-line.
Product Supply IssuesBaqsimi supply issues limited EU sales by $2MM-$3MM during the quarter.
Regulatory And Market ChallengesAMP-002 remains in limbo with no timelines to resolution, while other expected approvals have been delayed.
---
29A FAQ
What was Amphastar Pharmaceuticals’s price range in the past 12 months?
Amphastar Pharmaceuticals lowest stock price was €34.10 and its highest was €58.50 in the past 12 months.
What is Amphastar Pharmaceuticals’s market cap?
Currently, no data Available
When is Amphastar Pharmaceuticals’s upcoming earnings report date?
Amphastar Pharmaceuticals’s upcoming earnings report date is Mar 12, 2025 which is in 118 days.
How were Amphastar Pharmaceuticals’s earnings last quarter?
Amphastar Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported €0.902 earnings per share for the quarter, missing the consensus estimate of €0.928 by -€0.026.
Is Amphastar Pharmaceuticals overvalued?
According to Wall Street analysts Amphastar Pharmaceuticals’s price is currently Undervalued.
Does Amphastar Pharmaceuticals pay dividends?
Amphastar Pharmaceuticals does not currently pay dividends.
What is Amphastar Pharmaceuticals’s EPS estimate?
Amphastar Pharmaceuticals’s EPS estimate is €0.91.
How many shares outstanding does Amphastar Pharmaceuticals have?
Amphastar Pharmaceuticals has 48,081,432 shares outstanding.
What happened to Amphastar Pharmaceuticals’s price movement after its last earnings report?
Amphastar Pharmaceuticals reported an EPS of €0.902 in its last earnings report, missing expectations of €0.928. Following the earnings report the stock price went down -8.241%.
Which hedge fund is a major shareholder of Amphastar Pharmaceuticals?
Among the largest hedge funds holding Amphastar Pharmaceuticals’s share is Hussman Strategic Advisors Inc. It holds Amphastar Pharmaceuticals’s shares valued at 3M.
---
Amphastar Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€63.99 (47.21% Upside)
€63.99 (47.21% Upside)
Blogger Sentiment
Bullish
DE:29A Sentiment 88%
Sector Average 73%
Sector Average 73%
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-15.07%
12-Months-Change
Fundamentals
Return on Equity
23.85%
Trailing 12-Months
Asset Growth
0.04%
Trailing 12-Months
Company Description
Amphastar Pharmaceuticals
Amphastar Pharmaceuticals, Inc. engages in the development, manufacture, market, and sale of technically challenging and proprietary injectable, inhalation, and intranasal products. It operates through Finished Pharmaceutical Products, and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets and distributes enoxaparin, cortrosyn, amphadase, naloxone, lidocaine jelly, as well as various other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment manufactures and distributes recombinant human insulin and porcine insulin. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
---
29A Company Deck
---
29A Earnings Call
Q3 2024
0:00 / 0:00
---
29A Stock 12 Month Forecast
Average Price Target
€63.99
▲(47.21% Upside)
Technical Analysis
Amphastar Pharmaceuticals
―
ACADIA Pharmaceuticals
―
Catalyst Pharma
―
Heron Therapeutics
―
Amarin
―
Best Analysts Covering 29A
1 Year
1 Year Success Rate
15/18 ratings generated profit
1 Year Average Return
+26.29%
assigned a buy rating 28 days ago
Copying Tim Chiang's trades and holding each position for 1 Year would result in 83.33% of your transactions generating a profit, with an average return of +26.29% per trade.
---